Filtered library · Archetype
Earnings inflection · 195 dossiers
Dossiers classified as Earnings inflection — 195 names, each with its thesis, invalidation trigger and catalyst calendar.
All dossiers IRDM Iridium Communications Inc fresh MEDIUM Deal-arb: $27.00 cash plus a collared RKLB stock leg marks a $54.00 package against the 2026-08-24 close of $47.30, a 12.41% discount. The S-4/A filed 2026-08-24 finally dated the special meeting (2026-09-24), but RKLB at $68.28 sits just… CNC Centene Corporation fresh LOW Margin-repair guide raise of 2026-07-28 stays fully priced: the 2026-08-24 close of $65.65 is 2.7% under the 2026-08-14 close of $67.47 and 4.5% below the $68.72 52-week high, with no analyst target moved since Argus on 2026-08-11.… OSCR Oscar Health, Inc. fresh LOW Still maturing and range-bound: the 2026-08-24 close of $31.81 is the sixth session without a new high since the 2026-08-14 closing high of $32.76, and it sits 4.6% above the $30.40 consensus mean target. Short interest fell to 17.83M from… CRCL Circle Internet Group, Inc. fresh LOW Still a policy trade, but the first company-level support in weeks arrived: Bernstein's 2026-08-24 note reports USDC supply +$1.7B in a week after ~six months flat, reiterating $140 while Susquehanna raised to $92 on a Neutral. Circle has… OKLO Oklo Inc. fresh LOW Three straight cohort-driven sessions carried OKLO from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04, with no Oklo release behind any of them. The 2026-08-07 Q2 call is the binary. SMR NuScale Power Corporation fresh LOW Funded wait on one unsigned ENTRA1–TVA power purchase agreement, with the company silent for twenty days since the 2026-08-05 Q2 release. The 2026-08-24 close of $9.05 gave back most of the bounce off the 2026-08-18 floor at $8.64 and… PSNL Personalis, Inc. fresh HIGH The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus… ACLS Axcelis Technologies, Inc. MEDIUM Beat-and-raise on 2026-08-06 (Q2 rev $215.175M vs $204.985M est; Q3 guided $230.0M vs $214.846M) repaired the fundamental case, but price only recovered to the top of the July band at $140.15 (08-14), 26.9% under the $191.6 high. China… AGIO Agios Pharmaceuticals, Inc. MEDIUM Mitapivat SCD label-expansion binary into a 2026-11-01 PDUFA, now with a real commercial leg under it: Q2 mitapivat revenue $44.7M vs $26.03M consensus (2026-07-30), yet the tape gave the beat back — $33.56 close on 2026-08-14, RSI 35.8,… BBNX Beta Bionics, Inc. MEDIUM Q2 (2026-07-29) resolved the binary the right way: new patient starts rose sequentially (banded +10–20%) after Q1's decline, net sales $32.0M +38% YoY, FY26 gross-margin floor raised to 58.5–59.5%. The frame flipped from broken-growth to… BVS Bioventus Inc. MEDIUM Two weeks past the 2026-08-05 unsolicited-proposal disclosure the M&A leg is intact but undated: no committee update in 12 sessions, price consolidating at the 2026-08-21 close of $14.38 against the $15.26 high while RSI(14) unwound 70.5… CADL Candel Therapeutics, Inc. MEDIUM Pre-BLA re-rating re-armed: July's round-trip reversed, price reclaimed the June $11.36 high and closed 2026-08-14 at $11.72, 0.7% under the 52-week high, after the 8/13 Q2 print reaffirmed a Q4 2026 prostate BLA and $201.6M cash into Q1… CCC CCC Intelligent Solutions Holdings Inc. MEDIUM Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is… CDNA CareDx, Inc. MEDIUM Post-LCD estimate-revision leg is intact but the flow has moderated: no company headline between 2026-08-07 and 2026-08-21, yet a new closing high of $48.61 with RSI(14) down to 53.3 from 70.1. The 2026-08-30 LCD effective date is a… CGEM Cullinan Therapeutics, Inc. MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… CLDX Celldex Therapeutics, Inc. MEDIUM Single-asset binary: Phase 3 EMBARQ-CSU1/CSU2 topline guided to September/October 2026 at the 2026-08-06 print is the entire equity. The re-rating leg is built — 52-week high $44.87, three Overweight raises 07-29 to 08-07 — and has since… CMPS COMPASS Pathways Plc MEDIUM Clinical binary resolved 2026-07-07; what trades now is regulatory execution — rolling NDA completion guided Q4 2026, H1 2027 launch, $433.3M cash into 2028. The empty calendar just filled: FDA holds a public hearing 2026-09-14 on… DNTH Dianthus Therapeutics, Inc. MEDIUM Complement re-rate has gone quiet: no company disclosure since the 2026-08-04 Q2 print, a fresh 52-week high at $115.96 on a lower RSI than the early-August one, and the next dated binary — MoMeNtum MMN top-line — not until December 2026.… DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… DYN Dyne Therapeutics, Inc. MEDIUM maturing — nothing company-dated until the ~late-October Q3 print, then the 2027-01-21 PDUFA. ELF e.l.f. Beauty, Inc. MEDIUM Sell-side flipped from cutting to marking up in ten days — five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative… ELVN Enliven Therapeutics, Inc. MEDIUM Funded single-asset CML story broadening its shareholder base: Barclays initiated Overweight $78, William Blair Outperform and Mizuho raised to $73 all on 2026-08-18, yet the 2026-08-21 close of $59.82 sits 2.1% under the $61.11 high with… GERN Geron Corporation MEDIUM Narrative leg rotated on 2026-08-05/06: RYTELO revenue accelerated to $57.5M (+11% QoQ) and quarterly cash draw shrank to ~$14M from $60M, while management reframed IMpactMF's base case to the H2 2028 final OS analysis — so the… GHRS GH Research PLC MEDIUM Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next… HPP Hudson Pacific Properties, Inc. MEDIUM The refi binary now has a filed date: the 10-Q (2026-08-10) puts the Hollywood Media Portfolio loan maturity at 2026-09-09 with the longer-term extension still unresolved. Q2 beat ($0.35 Core FFO vs $0.26) and three August target raises… IDYA IDEAYA Biosciences, Inc. MEDIUM Approval leg intact but between catalysts: the OptimUM-02 win (HR 0.42, ASCO 2026-06-01) feeds a rolling NDA under FDA RTOR guided complete H2 2026, and Q2 (2026-08-04) showed ~$1.24B cash with runway into 2030. Nothing company-dated until… IKT Inhibikase Therapeutics, Inc. MEDIUM Tape has caught up to the story: after FDA Orphan Drug Designation (2026-07-23) and a Q2 print (2026-08-11) showing 43 sites live across 26 countries and $159.0M cash, IKT closed $2.41 on 2026-08-14, 2.4% off its 52-week high. What is… LBRX LB Pharmaceuticals Inc fresh MEDIUM Single-asset schizophrenia binary where the sell-side frame flipped above the tape: BMO $54 (2026-08-12), Stifel $53 (08-13), Clear Street $69 (08-20) against a 2026-08-21 close of $47.62 and an $51.5 eight-analyst average. The 2026-08-11… LRMR Larimar Therapeutics, Inc. MEDIUM Single-asset FA binary, now basing rather than breaking: the 2026-08-04 Q2 update held anaphylaxis at 10 of 43, reported no new urticaria after antihistamine premedication, and put cash at $156.3M with runway into Q3 2027. Rolling BLA… MBX MBX Biosciences, Inc. MEDIUM Single-asset execution story: oPTimize Phase 3 in canvuparatide is guided to start by 2026-09-30 and sites are already screening. Since 2026-08-15 the sell-side re-rated on no new data — consensus $88.36 across 12 analysts (2026-08-23) vs… MGTX MeiraGTx Holdings plc MEDIUM The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but… MIRM Mirum Pharmaceuticals, Inc. MEDIUM Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but… NGNE Neurogene Inc. MEDIUM Rett gene-therapy story is now fully financed — pro forma cash ~$360.2M after the July raise, runway into Q1 2029 — and the 2026-08-11 Q2 print added safety breadth (N=35 at 1E15 vg as of 08-10) but zero new efficacy. Next hard binary is… NKTR Nektar Therapeutics MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… NRIX Nurix Therapeutics, Inc. MEDIUM Roche-partnered BTK degrader moved from validation to execution: first patient in the registrational Phase 3 DAYBreak CLL-306 on 2026-08-04, RBC to $36 on 2026-08-10, price to a new 52-week high on 2026-08-14. Narrative still accelerating,… NVCR NovoCure Limited MEDIUM Post-TRIDENT commercial-inflection leg intact but undated: the 2026-07-23 Q2 print (rev $183.584M vs $172.437M cons., first positive adj. EBITDA $10.8M, FY guide to $710–725M) still sets the frame, and on 2026-08-22 Zacks flagged upward… ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… PGEN Precigen, Inc. MEDIUM PAPZIMEOS launch-ramp durability is the binary — the first FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026, and the now-confirmed Aug 4 Q2 print (announced Jul 21) grades whether the ramp compounds sequentially or… PTGX Protagonist Therapeutics, Inc. MEDIUM De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs —… PVLA Palvella Therapeutics, Inc. MEDIUM First-approved-therapy-for-microcystic-LM story still working: the 2026-08-04 Q2 update reaffirmed rolling-NDA completion in H2 2026 and potential approval H1 2027, and the stock closed $156.13 on 2026-08-14, 1.0% under its 52-week high.… RAPP Rapport Therapeutics, Inc. MEDIUM RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.… RCKT Rocket Pharmaceuticals, Inc. MEDIUM First clean RP-A501 datapoint in 15 months — three Danon patients dosed at the recalibrated 3.8×10¹³ GC/kg with no TMA or capillary leak (2026-08-03) — turned a bleeding chart into a mid-range one. The re-rate still needs the undated H2… RLAY Relay Therapeutics, Inc. MEDIUM Coverage-driven leg intact but thinning: HC Wainwright's $29 raise (2026-08-20) was the fourth in 14 days and the first that failed to make a new high, with the 2026-08-21 close at $19.44 versus a $20.75 52-week high. No dated company… RMAX Re/Max Holdings, Inc. fresh MEDIUM Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80… RPD Rapid7, Inc. MEDIUM Q2 (2026-08-10) flipped RPD from a pure take-private probe to a cost-out re-rating: ARR still -2.0% YoY at $824M, but EPS beat $0.44 vs $0.35, a 12% headcount cut targets 20% Q4 operating margin, and FY26 EPS guide went to $1.78-1.83.… SNDX Syndax Pharmaceuticals, Inc. MEDIUM Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance… TNET Trinet Group, Inc. MEDIUM The 2026-07-30 binary resolved bullish: Q2 ICR 86% vs 90%, adj EPS $1.55 vs $0.93 est, FY adj-EPS guide raised to $4.50-5.10. Shares made a 52wk high at $71.67 and sit 4.1% under it. The leg now being bought is durability, not recovery —… TRVI Trevi Therapeutics, Inc. MEDIUM Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional… TVTX Travere Therapeutics, Inc. MEDIUM Q2 beat on 2026-08-04 ($169.6M revenue vs $159.6M consensus; FILSPARI US sales +96% YoY to $141.1M) re-opened sell-side headroom — six target raises 08-05→08-10 into a $70–85 band while the 2026-08-14 close of $62.14 sits 1.0% under the… ULCC Frontier Group Holdings, Inc. MEDIUM Fuel-relief leg replaced by an earnings-delivery leg: the 2026-07-29 Q2 print put adjusted EPS at $(0.10) against a $(0.60)–$(0.45) May guide on record $1,279M revenue, and guided 2H to breakeven-or-better. The catch is that guide assumes… VSTM Verastem, Inc. MEDIUM Post-Q2 the narrative is confirmed and the tape has flattened: $6.74 on 2026-08-07 to $6.89 on 2026-08-21 while three banks cut targets with ratings held. The 2026-08-28 Oberland closing funds $50M inside 30 days; the October VS-7375… XNCR Xencor, Inc. MEDIUM Two overhangs closed in three weeks: the $105M Alexion settlement (2026-07-29) ended the Ultomiris dispute and pushed runway through 2028, and Q2 revenue of $51.2M vs $18.9M consensus (2026-08-05) drew three price-target raises on 08-06.… ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… ZURA Zura Bio Limited MEDIUM Q2 print (2026-08-11) added a third tibulizumab indication — polymyalgia rheumatica, NEXUS-PMR Phase 2 by YE2026 — and Wedbush ($22) plus Guggenheim ($20) raised targets on 2026-08-12; the $5.57 close on 2026-08-14 has not paid for it. The… AAPL Apple Inc. LOW July's rotation-crown has slipped — Polymarket now gives Apple 20% odds of ending 2026 as the largest company (7/24) and semis are breaking out again (NVDA 7/23). The live narrative is the 'anti-CapEx AI trade' as Alphabet turns… ABCL AbCellera Biologics Inc. LOW Binary resolved positive: ABCL635 Phase 2 hit both primaries on 2026-08-10 (placebo-adjusted −5.3 hot flashes/day, p<0.001), and the stock re-rated to a 52-week-high $11.38 close on 2026-08-14 at RSI 97.4. The company priced $200M of… ABEO Abeona Therapeutics Inc. LOW The 2026-08-13 Q2 print missed both lines — revenue $11.38M vs ~$12.24M, EPS -$0.35 vs -$0.23 — and price has given back 18.4% from the $7.46 high. But treated patients rose to five from three and the QTC network hit its seven-center 2026… ABVX Abivax SA LOW Post-binary single-asset UC biotech that has now lost the $125.00 placement shelf — 2026-08-14 close $118.96 — despite a positive 2026-07-30 pre-NDA FDA interaction. Sell-side sits ~$161.55 average against the tape, the CEO has framed a… ACB Aurora Cannabis Inc. LOW Frame flipped 2026-08-11: Curaleaf's unsolicited proposal — 0.3463 CURLF shares + US$0.75 cash, implied US$4.00, capped at US$5.00 — turned a broken Canadian LP into a live take-over situation. No formal bid has been commenced, the board… ACDC ProFrac Holding Corp. LOW Hormuz beta re-coupled in August: WTI settled $82.40 and Brent $88.52 on 2026-08-14 with the strait still shut, dragging ACDC to $5.37 at RSI 74.4. But the 2026-08-06 Q2 print missed (-$0.44 vs -$0.30), liquidity is ~$72M against $1,083.6M… AKBA Akebia Therapeutics, Inc. LOW VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —… ALHC Alignment Healthcare, Inc. LOW Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares… ALMS Alumis Inc. LOW Psoriasis leg is fully told — 2026-08-10 ONWARD3 48-week data (75% PASI 90 / 54% PASI 100) left the stock 16.5% under its $30.30 52-week high. The only re-rating leg left is the undated LUMUS Phase 2b lupus topline, reaffirmed for Q3 2026… ALOT AstroNova, Inc. LOW Terminal merger-arb pin. Arcline's $29.00 all-cash take-private cleared its HSR condition on 2026-07-31 and goes to a shareholder vote on 2026-08-25; the 2026-08-14 close of $28.91 leaves $0.09 of gross spread against a break tail toward… AMLX Amylyx Pharmaceuticals, Inc. LOW Single-asset binary, now inside the guided window: Amylyx reaffirmed on 2026-08-06 that Phase 3 LUCIDITY topline for avexitide in post-bariatric hypoglycemia arrives late August or early September 2026. Sell-side marked targets up into it… ANAB AnaptysBio, Inc. LOW The dateless wait acquired a docket: a 2026-07-28 stipulation set post-trial briefing to an Oct 20 Chancery argument, and ANAB has rebuilt from ~$54 (Jul 24) to $58.47 (Aug 14) on no company news. The written opinion deciding Jemperli… ANRO Alto Neuroscience Inc. LOW Precision-psychiatry TRD re-rate broke to new highs on a low-information 2026-08-12 Q2 print (EPS -$0.65 vs -$0.73 est) and two same-week target revisions (BTIG $37 Buy, Wedbush $26 Neutral). The 2026-08-14 close of $32.14 sits 0.5% under… APGE Apogee Therapeutics, Inc. LOW HSR expiry (2026-08-05) and shareholder approval (2026-08-11) cleared the last stated conditions on AbbVie's $135.11 all-cash takeout, so what trades now is terminal merger-arb carry into a company-guided Q3-2026 close — capped at the bid,… ARCT Arcturus Therapeutics Holdings Inc. LOW CSL exit hands back global KOSTAIVE plus flu/RSV/EBV rights, $12M cash and ~$16M of released liabilities, against $191.5M cash and runway guided through end-2028 — a platform-repossession re-rating that has run 91.3% in three months into… ARX Accelerant Holdings LOW Signed all-cash take-private at $20.25; the 2026-08-21 close of $19.59 leaves a fixed-price insurance-regulatory arb with the ceiling contractually set. Newly visible merger terms — go-shop ending 2026-09-22, outside date 2027-08-13… ATAI AtaiBeckley Inc. LOW Lilly takeout is now a process, not a story: DEFM14A filed, special meeting 2026-09-08, HSR filed 2026-07-29, close guided Q3 2026. The 2026-08-14 close of $7.26 sits $0.51 over the $6.75 cash leg, so all remaining return is an unread CVR… ATKR Atkore Inc. LOW Cyclical-repair frame is closed: the 2026-08-02 definitive all-cash merger with Prysmian at $95.00/share pins the stock, and the 2026-08-14 close of $93.80 leaves $1.20 of gross spread. The read is now completion timing — HSR plus… AVLN Avalyn Pharma Inc. LOW Post-IPO re-rating in an inhaled-antifibrotic single-asset story: the 2026-08-14 close of $39.25 is +118% over the $18.00 April IPO price with RSI(14) at 89.2, yet the MIST Phase 2b FVC readout that sets the value is guided to 2H 2027.… AVNS Avanos Medical, Inc. LOW Resolved, not pending: AIP completed the $25.00/share all-cash take-private on 2026-07-27 and AVNS ceased NYSE trading the same day (EV ~$1.272B). Holders received cash; there is no listed security, no narrative leg and no catalyst left.… AVTX Avalo Therapeutics, Inc. LOW The July soft catalyst has passed: Q2 landed 2026-08-06 and delivered a schedule — registrational Phase 3 in hidradenitis suppurativa initiating H1 2027 — so the post-LOTUS story now sits in a ~10-month gap with no company-dated clinical… AVXL Anavex Life Sciences Corp. LOW Governance, not approval, is the leg: PVG's six-nominee GOLD slate meets the board's WHITE slate at the 2026-09-24 annual meeting. Since 2026-08-15 the contest kept filing (8-K 08-17, DFAN14A 08-19) while price stalled — $3.24 on… BAK Braskem S.A. LOW Q2 2026 (released 2026-08-14) printed US$1.043B recurring EBITDA on a Middle East supply shock management called tactical — and the ADR closed $1.95, pricing the capital structure rather than the P&L. The 2026-06-26 São Paulo shield… BCAX Bicara Therapeutics Inc. LOW Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,… BHVN Biohaven Ltd. LOW Binary-catalyst biotech: the re-rate off the $7.48 Nov-CRL low stalled at ~$16 in early July and drifted to $13.85 on 2026-08-21. The undated 2H-26 RISE3 topline now races a live $350.0M J.P. Morgan ATM (424B5, 2026-05-04) against ~$270.5M… BIOA BioAge Labs, Inc. LOW The ESC venue hypothesis failed: ZEUS is absent from the published ESC 2026 Hot Line programme (Munich, 2026-08-28 to 08-31), so the full dataset that would separate NLRP3 from IL-6 blockade does not land in August and no substitute date… BOLD Boundless Bio, Inc. LOW Merger-arb wrapper, not an oncology stock: the object is a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. Week of 2026-08-14 added owners (ADAR1 13G at 8.8%) but no deal documents — still no S-4,… BTGO BitGo Holdings, Inc. LOW Broken IPO that cleared its 2026-07-21 lockup without a supply flood but is grinding on the $4.665 all-time low with no bounce; Goldman cut its target to $7.75, and the undated $100M Galaxy verdict plus the ~2026-08-26 Q2 print are the… BWIN The Baldwin Insurance Group, Inc. LOW Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,… BWMN Bowman Consulting Group Ltd. LOW Not a growth story — a cash-deal spread. Bernhard Capital's $43.00 all-cash take-private (signed 2026-08-10) caps the name; the 2026-08-21 close of $42.61 is $0.39 under it, down from a $0.70 gap on 2026-08-14. The go-shop expires 5:00… CBZ CBIZ, Inc. LOW Deal-completion story now, not an operating one: the 2026-08-21 close of $54.66 sits $0.34 under the signed $55.00 all-cash terms, in from $0.54 on 2026-08-14. The go-shop expiring 11:59pm ET 2026-08-27 is the only mechanism that can print… CCRN Cross Country Healthcare, Inc. LOW Situation settled: the Knox Lane take-private became effective 2026-07-21 at $13.25 cash, Nasdaq suspended trading that morning and filed Form 25 the same day. No listed security, no residual claim, no forward catalyst — any CCRN bar dated… CCXI Churchill Capital Corp XI LOW De-SPAC humanoid pure-play now maturing: Unitree's 2026-08-19 STAR debut (+487% close, ~$53B) lifted CCXI for one session before the move fully round-tripped — $17.07 on 2026-08-14 to $14.57 on 2026-08-21, RSI 73.4 to 43.5. Still no public… CGC Canopy Growth Corporation LOW The rescheduling binary CGC trades on came and went: the DEA hearing closed 2026-07-15 with no verdict, briefs due 2026-08-17 and the ALJ recommendation undated into H2 2026, likely litigated into 2027. Shares closed $0.89 on 2026-07-24,… CHYM Chime Financial, Inc. LOW Busted-IPO fintech: operations accelerating (Q1 rev +25% to $647M, first GAAP profit, FY guide raised to $2.66–2.69B) but the stock trades ~19% below its $27 IPO and bases near post-IPO lows — a compressed multiple, not an accelerating… CLYM Climb Bio, Inc. LOW Anti-CD19 autoimmune re-rate: budoprutug's 2026-06-11 EHA ITP data (>90% B-cell depletion, n=15) plus $239.2M cash funding into 2H 2028 lifted CLYM to a 52-week high at $16.33 on 2026-08-14. The 2026-09-03 R&D Spotlight (CLYM116 Phase 1… CNMD CONMED Corporation LOW Six weeks on, the deal leg is still the only unresolved one: no process headline since 2026-07-10, no sell-side action since 2026-07-30, no company event dated inside 30 days — yet price drifted to $51.07 on 2026-08-21, 10.9% above the… CNTA Centessa Pharmaceuticals plc LOW Closed cash-plus-CVR takeout; nothing trades. Lilly's scheme ($38.00 cash plus a non-transferable CVR of up to $9.00) went effective 2026-06-24, Form 15-12G dated 2026-07-06. New since the last note: ClinicalTrials.gov lists a Phase… CORT Corcept Therapeutics Incorporated LOW Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry… CRNX Crinetics Pharmaceuticals, Inc. LOW Not a narrative any more: the Vertex $85.00/share cash takeout cleared HSR on 2026-08-12, the stockholder vote is 2026-08-28, and closing is guided to early September. At the 2026-08-14 close of $84.70 the gap to terms is $0.30 against… CRTO Criteo S.A. LOW Takeover-premium leg is dead and the tape kept going: the 2026-07-06 Vista/Quinti gap is fully filled, no party has confirmed anything in 46 days, and the 2026-08-05 guide cut re-based FY26 contribution ex-TAC to $1.034–1.058B from… CRVS Corvus Pharmaceuticals, Inc. LOW Calendar still empty until 2027 after the 2026-08-06 push-out (PTCL futility Q1 2027, no data released; SIERRA1 topline Q3 2027), but the tape has recovered: $14.46 close on 2026-08-21 with RSI 62.4 versus $13.92 and RSI 47.5 on… DFTX Definium Therapeutics, Inc. LOW Voyage GAD read out positive on 2026-08-12 — HAM-A 5.4 points over placebo at Week 12, p<0.0001, Cohen's d 0.81 — and eight target actions followed inside seven sessions. Yet the 2026-08-21 close of $44.91 sits under the pre-readout $46.14… DSGN Design Therapeutics, Inc. LOW A new 52-week high of $15.94 printed in August with no company release since the 2026-08-03 Q2 update, which pushed the next hard data to Q1 2027. RSI(14) 73.9 at the $14.99 close (2026-08-21) and +21.9% for the month, into a 30-day… EPC Edgewell Personal Care Company LOW Two legs: a refused $30 take-private approach (2026-06-22) and a first clean quarter (fiscal Q3 organic +1.1%, adjusted EPS $0.72 vs $0.62). Sixty days on there is no competing bid, no process and no 13D, and the shares have coiled within… ERAS Erasca, Inc. LOW Funded pan-RAS story with part of its calendar restored: the 2026-08-11 Q2 release dates ERAS-4001 BOREALIS-1 preliminary Phase 1 data to H2 2026, ahead of the H1 2027 ERAS-0015 cut. But the 2026-08-21 close of $17.63 sits on the $17.50… ESPR Esperion Therapeutics, Inc. LOW Resolved and off the tape. ARCHIMED's take-private closed 2026-07-13 at $3.16 cash plus a non-tradeable CVR of up to $100M; Nasdaq was asked to file Form 25 the same day and reporting duties are being suspended by Form 15. The early-August… EVH Evolent Health, Inc LOW The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which… FBRX Forte Biosciences, Inc. LOW Deal-spread endgame: HSR expired 2026-08-18 (SC 14D9/A filed 2026-08-19), leaving only the >50% minimum tender before argenx's $77.00 all-cash offer expires 2026-08-26. The 2026-08-21 close of $76.92 leaves $0.08 of gross gap. Upside is… FDMT 4D Molecular Therapeutics, Inc. LOW Wet-AMD one-and-done durability narrative accelerating on the 2026-07-18 PRISM 2-year data (78% injection-burden reduction, 2.7 vs 12.0 projected, n=30) plus a 2026-07-31 Buy initiation at PT $37 and a 2026-08-13 Q2 beat. Price is 5.5% off… FIG Figma, Inc. LOW Design incumbent re-rated as an AI winner (BofA Buy, $30 PT, 7/7) rather than an AI casualty, yet the stock churns below its 100/200-day moving averages with heavy short interest into its first public earnings print on 8/5 — that print,… FOUR Shift4 Payments, Inc. LOW Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary… FWRD Forward Air Corporation LOW Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited… GBTG Global Business Travel Group, Inc. LOW Take-private in its final leg: stockholders adopted the $9.50 Long Lake merger on 2026-08-03, and the 2026-08-14 close of $9.46 leaves $0.04 gross against a roughly 37% break tail to the unaffected $5.93. Only undated offshore regulatory… GCO Genesco Inc. LOW The operating turnaround is real but priced, and its one asymmetric leg — the activist proxy fight — lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the… GLUE Monte Rosa Therapeutics, Inc. LOW ZEUS (ziltivekimab, MACE HR 0.99) failed on 2026-07-31 and took GLUE −27.16% to $16.52, its worst session on record, because the hsCRP-to-outcomes link under MRT-8102's ASCVD story is exactly what ZEUS could not demonstrate. Platform,… GSHD Goosehead Insurance, Inc. LOW Post-print re-rating extended on no new information: the 2026-08-21 close of $72.52 is above UBS's $72, above KBW's $72 and above the ~$71 aggregator consensus, while founder-side Class B conversions sell into it. No dated company catalyst… HOV Hovnanian Enterprises, Inc. Class A LOW The housing-bill leg is spent — the Act auto-enacted 2026-07-11 and nothing dated has replaced it — yet HOV has re-rated to $137.78 (2026-08-07), 11.8% off the $156.16 high, on no company news. The confirmed 2026-08-20 Q3 print (quarter… HROW Harrow, Inc. LOW Post-Q2 this is a leverage-and-execution show-me: the reaffirmed $350–365M FY guide needs H2 to roughly double the $114.9M booked in H1, against $292.4M loans payable net and $14.8M equity. The 2026-08-20 IHEEZO comfort data supports the… HZO MarineMax, Inc. fresh LOW Deal pin rather than a growth story: the $53.00 all-cash Safe Harbor/Blackstone Infrastructure take-private, signed 2026-08-09, leaves $0.80 to terms at the 2026-08-21 close of $52.20. What trades now is HSR/FDI clearance and a shareholder… IHRT iHeartMedia, Inc. LOW M&A leg is dead — no SiriusXM headline since the 2026-05-29 NYT "stalled" report and the April spike fully round-tripped ($6.33 high → $3.86 on 2026-08-07, -39%). What is left is a binary: Q2 print 2026-08-10 after the close is the first… IMMX Immix Biopharma, Inc. fresh LOW Single-asset CAR-T regulatory story: NXC-201 posted a 95% CR rate (19/20) in NEXICART-2 on 2026-05-21 and holds FDA Breakthrough Therapy Designation from 2026-01-28, with a BLA guided for 2026. Price closed 2026-08-21 at its 52-week high… IMRX Immuneering Corporation LOW Busted-catalyst pancreatic biotech: atebimetinib's 17.3-mo single-arm 1L OS is real, but the Phase 3 binary is mid-2028 and the tape keeps fading post-ASCO ($5.11→$4.32 in two weeks) even as targets climb to $18–$30. Cheap… INBX Inhibrx Biosciences, Inc. LOW Non-dilutive bridge into the 2027-04-14 PDUFA, with one item pulled forward: the 2026-08-13 Q2 release moved the INBRX-106 HNSCC PFS readout into Q3 2026 and dated the CRC registrational FDA meeting to Q4 2026. But the two-week advance… IRWD Ironwood Pharmaceuticals, Inc. LOW Post-print drift: the 2026-08-06 binary resolved with FY26 guidance raised (revenue $460–485M, adjusted EBITDA above $310M) but both reported lines missing consensus, and two weeks on the stock is unchanged at $4.29, 20.4% under the $5.39… ITGR Integer Holdings Corporation LOW Signed-deal instrument since 2026-08-03: KKR's $127.00 all-cash agreement leaves $1.80 above the 2026-08-21 close of $125.20 (~1.4%), unchanged from two weeks earlier. The paperwork stage has begun with no paperwork — no merger proxy on… IVA Inventiva S.A. LOW Single-asset MASH binary, still dormant: zero company news in the 30 days to 2026-08-23, with the undated Q4 2026 NATiV3 topline carrying the whole equity. RSI(14) firmed to 66.7 at the $4.68 close on no flow, while the $4.40 June offering… JBIO Jade Biosciences, Inc. LOW The post-Q2 revision leg round-tripped: $24.71 on 2026-08-14 back to $21.34 on 2026-08-21, with the 2026-08-11 target raises (Wedbush $47, Jefferies $48 from $40) marking the high rather than starting a leg. The July shelf near $21 is now… JBLU JetBlue Airways Corporation LOW Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B… JOBY Joby Aviation, Inc. LOW eVTOL cert story still advancing (FAA TIA testing, 2026 Dubai target) but the trade rolled over: ~$8 testing support, down ~33% since June 1, recovery base gone, CFO sold ~half his stake June 8, consolidation coverage marks sentiment… KALV KalVista Pharmaceuticals, Inc. LOW Resolved cash takeout, not a live security: Chiesi's $27.00/share acquisition closed 2026-06-11, KALV delisted the same morning, Form 15-12G filed 2026-06-22, and Rule 12g-4 registration termination lands ~2026-09-20. The 2026-06-10 close… KOD Kodiak Sciences Inc LOW Binary-catalyst redemption arc now inside its final month: DAYBREAK wet-AMD one-year topline guided September 2026. Price keeps stepping down through good news — $42.64 (07-17) to $41.35 (08-14) to $38.33 (08-21), -17.5% from the $46.44… KURA Kura Oncology, Inc. LOW The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A… LOVE The Lovesac Company LOW The ~$17 reclaim failed: a $17.29 close on 2026-08-14 gave way to $16.07 on 2026-08-21, back under the 50-day at $16.79, while short interest decayed to 3.03M shares (28.35% of float) from ~4.05M on Jan–Mar data. The ~2026-09-10 Q2 FY27… LPRO Open Lending Corporation LOW Terminal, not fading: ANV's $3.15 all-cash tender expired 2026-07-27 with ~85.65% tendered, shares accepted 2026-07-28, §251(h) merger consummated 2026-07-30. Last public close $3.14 on 2026-07-29. As of 2026-08-23 nothing has reopened it… LQDA Liquidia Corporation LOW The prior break level triggered: LQDA closed the week at $68.62 on 2026-08-21, through the $70 July shelf and the 08-13 low close of $72.10, despite six post-print targets at $90–$111. Q2 sales grew +31% QoQ, but the re-rating leg is… MAZE Maze Therapeutics, Inc. LOW APOL1 kidney precision-medicine story intact, but the 2026-08-11 Q2 print emptied 2026 of catalysts: MZE782 PKU topline pushed to 2027 and CKD Phase 2 start to H1 2027, leaving only HORIZON's three 10–15 patient cohorts in… MESO Mesoblast Limited LOW Platform-inflection story re-accelerated on operational news rather than data: the 2026-08-17 last-patient-treated release for the 350-patient CLBP Phase 3 carried the ADR from $15.60 (08-14) to $17.00 (08-21), reclaiming the July shelf… MGM MGM RESORTS INTERNATIONAL LOW Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low — so the trade is now a bump handicap, not a growth story. At… MKTX MarketAxess Holdings, Inc. LOW ICE's $167.00 all-cash agreement (signed 2026-07-30) has fully converted MKTX into a spread instrument, and the spread has drifted wider: $167.00 less the 2026-08-21 close of $162.11 leaves $4.89 gross against an H1 2027 guided close.… MMYT MakeMyTrip Limited LOW MakeMyTrip's mid-year recovery bounce has stalled: after reclaiming the 200-day near $55, MMYT rolled back to ~$49, below both the 50- and 200-day, straight into an August 3 Q1 FY2027 print where consensus models EPS down ~76% YoY on ~137x… NUVL Nuvalent, Inc. LOW Closed, not pending: GSK completed the $124 all-cash acquisition on 2026-07-15 after 91.3% of shares were tendered by the 2026-07-14 expiry; trading was suspended 2026-07-15 and Form 25 delisting requested. No US-listed NUVL equity remains… ODD ODDITY Tech Ltd. LOW Compounder narrative is dead (Q1 revenue -26%, first orders -50%) and the drift continued on no news at all: $14.12 on 2026-08-07 to $13.22 on 2026-08-21, now sitting on the $13 shelf. The 2026-09-09 pre-market Q2 print is the only dated… OGN Organon & Co. LOW Deal-pinned arb, now purely regulatory: the $14.00 all-cash Sun Pharma offer was approved by holders 2026-07-23 and the 2026-08-21 close of $13.75 leaves $0.25, ~1.8% gross, into a stated early-2027 close. Upside is capped by contract; a… OLPX Olaplex Holdings, Inc. LOW Closed by event and now confirmed from the buyer's side: Henkel's all-cash takeout completed 2026-07-07 at $2.06 per share, Nasdaq delisting and a Form 15-12G followed, and Henkel's 2026-08-06 half-year report carries no brand-level… ORIC Oric Pharmaceuticals, Inc. LOW mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is… PANL Pangaea Logistics Solutions Ltd. LOW Dry-bulk recovery is in the P&L but not the tape: Q1 2026 (2026-05-11) adjusted EBITDA +70% YoY to $25.2M on $15,252/day TCE, yet the stock closed $7.42 on 2026-08-07, 20.1% under the $9.29 52-week high. The 2026-08-10 Q2 print is the… PAYO Payoneer Global Inc. LOW Pure merger-arb, now fully scheduled: HSR early termination granted 2026-07-28 and the 2026-08-11 definitive proxy set the shareholder vote for 2026-09-14, yet the 2026-08-14 close of $7.13 still sits $0.27 under Nuvei's $7.40 all-cash… PEB Pebblebrook Hotel Trust LOW The 2026-07-29 binary resolved bullish — Q2 RevPAR +6.5%, AFFO $0.68, FY guide raised to $345–353M EBITDAre — and the stock still has not made a new high, closing 2026-08-14 at $18.25, 7.6% under the $19.75 high with RSI 35.3. Q3 guidance… PESI Perma-Fix Environmental Services, Inc. LOW Binary resolved 2026-08-12 in two directions: the H2C master IDIQ is signed but issues no dollars before 2027-01-01, while Q2 printed a $2.5M gross loss and unalleviated going-concern doubt. No company release since 2026-08-12 and no dated… PI Impinj, Inc. LOW Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high — but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS… PLAY Dave & Buster's Entertainment, Inc. LOW Turnaround narrative dead since the 2026-06-15 comp miss (-5.4%, EPS $0.16 vs ~$0.598); CEO seat changed hands 2026-08-03 with CFO Darin Harper replacing Tarun Lal. Price stabilized off the $9.40 July low to $10.19 on 2026-08-14, RSI 47.5,… PLSE Pulse Biosciences, Inc fresh LOW Timeline-compression leg extended by broker coverage rather than new data: Needham initiated Buy with a $58 target on 2026-08-17 and price closed 2026-08-21 at $50.42, a fresh 52-week high with RSI 82.5, above three of four published… PLTK Playtika Holding Corp. LOW The control-premium bid is gone and the markdown extended: the 2026-08-21 weekly close of $2.37 took out the $2.51 shelf, RSI(14) 12.9, 44.4% under the $4.26 52-week high. The one new disclosure is financing rather than a sale — 2026-08-18… PYPL PayPal Holdings, Inc. LOW Bid became negotiation: WSJ (2026-08-14) reports Stripe/Advent in active talks and weighing a raise over the rejected $60.50 offer, while the 2026-07-28 Q2 beat (EPS $1.38 vs $1.28) and a raised FY26 guide lifted standalone value. At… QDEL QuidelOrtho Corporation LOW Deal-rumor leg fully retraced and still unresolved: the 2026-08-06 cut (FY26 adj EPS to $0.65–0.90 from $1.80–2.00, FCF guide withdrawn) took price back to the $13.79 pre-rumor shelf, and the $14.74 close of 2026-08-21 is drift on no… QRVO Qorvo, Inc. LOW US antitrust cleared 2026-08-01 and Skyworks' post-print recovery to $69.62 lifted implied consideration to $99.33 (0.960 SWKS + $32.50 cash) against QRVO's $98.11 close — about 1.2% gross for underwriting China's SAMR and Korea's KFTC,… QURE uniQure N.V. LOW FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on… RAMP LiveRamp Holdings, Inc. LOW Shareholder gate cleared 2026-08-17: 51,578,202 shares voted to adopt versus 60,073 against, leaving CFIUS, HSR and non-US clearances as the only unconfirmed conditions on Publicis' $38.50 cash offer. The 2026-08-21 close of $37.58 sits… RARE Ultragenyx Pharmaceutical Inc. LOW The +50% June reset rally round-tripped from ~$33.46 to $28.62 (2026-07-21), parking price back on the breakout shelf ahead of two binary FDA decisions: DTX401 (GSD Ia) PDUFA Aug 23 and UX111 (Sanfilippo A) PDUFA Sep 19. The July 30 Q2… RBLX Roblox Corporation LOW Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary — it needs a DAU… REAX The Real Brokerage, Inc. fresh LOW Hypergrowth brokerage story has decelerated (Q1 rev +32% vs 70%+ historically, a forecast miss) and the stock sits near 52-week lows after the $880M RE/MAX deal spooked investors on dilution. The read is now a binary consolidation bet, not… RIVN Rivian Automotive, Inc. LOW The 2026-07-30 binary resolved bullish — revenue $1.658B (+27% YoY), FY delivery guide raised to 65,000–70,000 — and the market gave the entire 2026-07-31 pop back, closing 2026-08-14 at $15.36, under the $15.50 July offering price.… RLMD Relmada Therapeutics, Inc. LOW The level this coverage was framed around broke: the 2026-08-21 weekly close of $4.63 is under the $4.75 March PIPE strike, and it broke on no disclosure. With the 2026 clinical calendar emptied on the 2026-08-06 call, what remains is a… RLYB Rallybio Corporation LOW No new filing since the 2026-08-06 10-Q: as of 2026-08-23 the 2026-07-15 S-4 is still not effective, with no record date or meeting date set. The 2026-08-21 close of $16.83 sits ~7% above the ~$15.68/share implied by the S-4's $83.2M Net… RPAY Repay Holdings Corporation LOW The bid discount narrowed on an operating headline: the close ran $3.66 (2026-08-14) to $4.01 (2026-08-21) after REPAY joined Visa Platform Connect on 2026-08-19, leaving Forager's rejected $5.25 cash proposal ~31% above the tape with no… RZLT Rezolute, Inc. LOW A 10.7% week to $5.09 on 2026-08-21 with zero company news since the 2026-07-21 conference notice — the bid arrived via Friday-gainer screens, not a disclosure. The 2026-06-02 upLIFT interim (6 of 8 responders) is still the entire story,… SAFT Safety Insurance Group, Inc. LOW Mapfre's $105.00 all-cash deal (signed 2026-07-23) has pinned the tape: the 2026-08-14 close of $103.35 leaves ~1.6% gross to the contract price, down from ~4.6% on 2026-07-24, with no publicly reported approval milestone in between. The… SANA Sana Biotechnology, Inc. LOW Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the… SEER Seer, Inc. LOW The take-private ladder has stalled into a stand-off: the $2.55 Radoff-JEC bid lapsed unanswered on 2026-08-10, and the group's 2026-08-13 release demanding the board disclose an evaluation timeline has drawn no company reply through the… SLDB Solid Biosciences Inc. LOW Post-Sarepta DMD vacuum trade now in a waiting phase: the guided mid-2026 accelerated-approval update never landed — the 2026-08-06 Q2 release moved the FDA meeting to late Q4 2026 while INSPIRE dosing grew to 53 (as of 2026-08-04). Price… SMMT Summit Therapeutics Inc. LOW Two positive headlines on 2026-08-12 — Akeso's third China approval and a Leerink upgrade — left the stock lower: the 2026-08-21 close of $13.16 sits under the 2026-08-14 close and just above the $12.55 52-week low. The dated binary is the… SMTI Sanara MedTech Inc. LOW Merger-arb instrument since MIMEDX's 2026-07-29 agreement ($33.00 cash + 0.4735 MDXG per share). The 2026-08-11 Form 425 disclosed a 2027-07-29 outside date, a $22.5M reverse termination fee and 38.9% voting lock-up; at the $34.45 close… SPRY ARS Pharmaceuticals, Inc. LOW Single-product epinephrine name whose one catalyst — a July no-prior-auth formulary add for neffy — came and went unpaid; the stock has since broken its old $6.66 52-week low to fresh lows near $6. The neffy ramp is real but the access… STAA STAAR Surgical Company LOW Structure broken, no dated catalyst before the ~2026-10-07 pre-release window. STM STMicroelectronics N.V. LOW The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA… STRO Sutro Biopharma, Inc. LOW Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June… SYNA Synaptics Incorporated LOW Standalone story ended at the 2026-06-25 all-stock takeout; The week to 2026-08-21 proved it — ON -10.2%, SYNA -10.1%, discount still ~2.5% (1.350 x $74.21 = $100.18 vs $97.66). The S-4 filed 2026-08-21 puts the vote on the clock and… TBRG TruBridge, Inc. LOW Closed and now formally deregistered: the IKS Health merger became effective 2026-07-09 at $26.25/share cash, Form 25 filed the same day, Form 15-12G on 2026-07-24. The adjusted series ends 2026-07-08 at $26.24. A screen still surfacing… TECH Bio-Techne Corp LOW Closed merger-arb pinned $0.60 under Merck KGaA's $73.00 all-cash bid — 2026-08-14 close $72.40, also the 52-week high. Q4 printed 08-12 with no call and no FY27 guidance; Wells Fargo folded to a $73 target on 08-13. Coverage is fully… TENX Tenax Therapeutics, Inc. LOW Phase 3 binary resolved negative: LEVEL missed its primary (6MWD +3.5m, p=0.63) and key secondary on 2026-08-10; four desks cut within 24h and the target band went from $27–$50 to $4–$5. Narrative is dead. What is left is a balance-sheet… TLRY Tilray Brands, Inc. LOW Reform binary spent without resolving: the DEA hearing closed 2026-07-15 with only a 2026-08-17 briefing deadline and no ALJ timeline, so Schedule III is now an open-ended administrative process. TLRY printed a fresh 52-week low of $4.20… TMC TMC the metals company Inc. LOW The deep-sea-mining reshoring leg is broken: TMC has cut through the $3.93 prior 52-week low to a fresh $3.57 low near $3.74, roughly -67% from the $11.35 high, with no bid and no near-term catalyst. The decisive NOAA license decision is… TSHA Taysha Gene Therapies, Inc. LOW Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 — pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next… UI Ubiquiti Inc. LOW Broken parabola gone flat: six weeks of $530–$570 chop after the May 8 print (GM 47.0%, rev +18.7%, but EPS $3.88 vs ~$4.42 whisper) with zero scheduled catalyst until the Q4 FY26 report on 2026-08-21. Fundamentals intact, tape dead,… USO United States Oil Fund, LP LOW Hormuz has been shut since late February and USO still closed 2026-08-14 at $126.60, 17.2% under its $152.96 high — the market has stopped paying for escalation. The 2026-08-12 EIA +17.423M bbl build and OPEC's demand-growth cut to 580K… UTZ Utz Brands, Inc. LOW Event fired and fully priced: the 2026-08-14 close of $14.17 sits $0.08 under Intersnack's $14.25 all-cash offer, and the 2026-08-05 Q2 miss moved nothing. What remains is a sub-1% gross spread to a company-guided Q4 2026 close against a… VECO Veeco Instruments Inc. LOW Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes cleared 2026-02-06, only China SAMR remains before the 2026-09-30 outside date. ACLS's slide to ~$134 de-pegged VECO to a premium over the exchange ratio (~$48) —… VERI Veritone, Inc. LOW Enterprise-AI growth story broken: FY2026 revenue guide cut ~23% at the midpoint to $100–115M on 2026-08-13 vs $135.032M consensus, ARR flat at $62.0M. What is left is a refinancing binary — $45.6M of 1.75% converts mature 2026-11-15… VIR Vir Biotechnology, Inc. LOW Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and… VKTX Viking Therapeutics, Inc. LOW The ~$34 line from July gave way — $33.19 close on 2026-08-14, -21.2% from the $42.13 high. Only company-guided 2026 event left is the VK2735 maintenance-dose readout (3Q26); pivotal VANQUISH topline is 2027. JPMorgan cut its target to $65… VREX Varex Imaging Corporation fresh LOW Signed all-cash takeout: Teledyne agreed on 2026-08-10 to buy Varex at $18.90/share (~$1.1B). The 2026-08-14 close of $18.49 leaves roughly $0.41 of gross gap into a closing guided for early calendar 2027 with a 2027-05-10 outside date.… VRNS Varonis Systems, Inc. LOW Take-private leg is aging without confirmation: two months after the 2026-06-23 Bloomberg report there is no bidder, price or 13D, an unexplained 9.3% mid-August pop round-tripped inside six sessions, and the 2026-08-21 close of $41.23… VSH Vishay Intertechnology, Inc. LOW Cycle-turn re-rate has fully round-tripped: down ~46% from $69.47 to the high-$30s, now under the $50 June placement and below every covering analyst's target. Q1's 1.34 book-to-bill and $1.6B backlog were real but sit at ~35x forward into… WDAY Workday, Inc. LOW The 2026-08-27 Q2 FY27 print — cRPO against a guided 13.5–14.5% band — is the binary that lands first. WGS GeneDx Holdings Corp. fresh LOW Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed Aug 3 Q2 print (blended ARR vs the ~$3,300 baseline) is the binary — the same day as the… WING Wingstop Inc. LOW Two analyst target cuts in ten days (Wells Fargo to $170, DA Davidson to $200) into the 2026-07-29 Q2 print signal de-risking ahead of the H2 comp-turn binary; a ~50% relief bounce off the $116.35 low is unproven, and the print — not… XENE Xenon Pharmaceuticals Inc. LOW Q2 (2026-08-06) cleared the last procedural gate — FDA pre-NDA meeting completed, azetukalner FOS NDA still guided to Q3 2026, cash $1,245.1M — and the stock still closed 2026-08-14 at $62.35, 12.1% below the $70.96 July high with RSI… YSS York Space Systems Inc. LOW Roll-up/defense-growth leg is broken: the 2026-08-13 FY26 guide cut to $375–405M from $545–595M (vs $560.341M consensus) is the first company-sourced confirmation the revenue base moved. Close $10.93 on 2026-08-14, -54.5% over 3m, RSI… ZS Zscaler, Inc. LOW Post-crash recovery leg is complete: the 2026-05-27 gap-down (~31.5% on a 16–17% FY27 growth frame) has been fully retraced to $181.75 (2026-08-21) with RSI 71.5, and six houses marked targets to $200–225 between 08-17 and 08-21 on no new… ZVRA Zevra Therapeutics, Inc. LOW The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now…